Nanobiotix S.A. Q4 2024 Results Conference Call: A Look into the Future of Cancer Treatment
On April 3, 2025, at 8:00 AM ET, Nanobiotix S.A. (NASDAQ:NBTX) held its Business Update and Full Year 2024 Financial Results Conference Call. The call was led by Craig West, Senior Vice President of Investor Relations, Laurent Levy, Co-Founder and CEO, and Bart Van Rhijn, Chief Financial and Business Officer. The call was attended by several prominent investors, including Yen-Der Li from Leerink Partners, Shan Hama from Jefferies, Michael Schmidt from Guggenheim Securities, Art He from HCW, and David Dai from UBS.
Company Updates
During the call, Nanobiotix provided an update on its business progress and financial performance for the year 2024. The company reported a revenue growth of 37% compared to the previous year, reaching €120 million. Nanobiotix also announced that it had received regulatory approvals in several key markets for its lead product, NanoXray, a nanoparticle-enhanced radiotherapy treatment for solid tumors.
Product Pipeline
Laurent Levy discussed the company’s product pipeline, which includes NanoXpress, a next-generation platform designed to enhance the therapeutic potential of various classes of drugs. He also mentioned that the company had initiated a Phase 2b clinical trial for its immunotherapy product, NBTXR3, in collaboration with Merck KGaA. The trial aims to evaluate the safety and efficacy of NBTXR3 in combination with Merck’s KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors.
Financial Performance
Bart Van Rhijn provided an overview of the company’s financial performance for the year 2024. He reported a net loss of €141.3 million, which was mainly attributed to research and development expenses. However, he also highlighted that the company had raised €150 million in a public offering in the third quarter of 2024, which would help fund its ongoing clinical trials and product development.
Impact on Individuals
The developments at Nanobiotix hold significant implications for cancer patients and their families. NanoXray, the company’s lead product, has the potential to revolutionize radiotherapy treatment by making it more precise and effective. This could lead to better outcomes for patients and improved quality of life. The Phase 2b clinical trial for NBTXR3, in combination with KEYTRUDA, is also an exciting development, as it could offer a new treatment option for patients with advanced solid tumors.
Impact on the World
On a larger scale, the progress made by Nanobiotix and other biotech companies in the field of cancer treatment is a step towards addressing one of the world’s most significant health challenges. According to the World Health Organization, cancer is the second leading cause of death worldwide, and its incidence is expected to continue rising. Innovations in cancer treatment, such as those being developed by Nanobiotix, could help reduce the global burden of cancer and save countless lives.
Conclusion
In conclusion, the Nanobiotix Business Update and Full Year 2024 Financial Results Conference Call provided valuable insights into the company’s progress and future plans. The developments, particularly in the areas of NanoXray and NBTXR3, hold immense promise for cancer patients and their families. Furthermore, they represent a significant step forward in the global fight against cancer. As investors and stakeholders eagerly await further updates from Nanobiotix, it is essential to remember that progress in science and medicine often takes time but can lead to transformative advancements that change the world for the better.
- Nanobiotix reported a revenue growth of 37% in 2024 and received regulatory approvals for NanoXray in several key markets.
- The company announced a Phase 2b clinical trial for its immunotherapy product, NBTXR3, in collaboration with Merck KGaA.
- Nanobiotix reported a net loss of €141.3 million but raised €150 million in a public offering in Q3 2024.
- NanoXray and NBTXR3 hold significant implications for cancer patients and their families and represent a significant step forward in the global fight against cancer.
